+1-800-267-5763
As biosimilars begin to enter the Canadian retina space, many ophthalmologists are asking: how do these agents compare to reference biologics—and what should we consider before making the switch?
Join renowned retina specialists Dr. Mike Klufas and Dr. Sophie Bakri for a 90-minute webinar that dives into the practical realities of biosimilar use—from clinical trial data to real-world adoption strategies.
📅 Date: May 29, 2025
🕒 Time: 7:00 PM ET
⏳ Duration: 90 minutes
Dr. Michael Klufas is a vitreoretinal surgeon at Wills Eye Hospital and Associate Professor of Ophthalmology at Thomas Jefferson University. He has authored over 90 publications and is a principal investigator in clinical trials on AMD, diabetic eye disease, biosimilars, and gene therapy. A graduate of Brown University and Weill Cornell, Dr. Klufas is a frequent speaker at national and international meetings.
Dr. Sophie J. Bakri is Chair of Ophthalmology at Mayo Clinic and holds the Whitney and Betty MacMillan Professorship. A vitreoretinal surgeon and Wharton MBA graduate, she has authored over 230 peer-reviewed papers and leads multiple clinical trials on retinal disease. She has received numerous accolades, including the AAO Senior Achievement Award and Retina Hall of Fame induction.
This webinar is ideal for retina specialists, general/comprehensive ophthalmologists, fellows, residents, and medical students seeking a deeper understanding of biosimilars and their role in retinal disease management.
In addition to these experts, the Biosimilars Planning Committee will be joining them in a panel discussion at the end of the webinar. We are excited to have Dr. Parnian Arjmand, Dr. Vlad Diaconita, Dr. Bryon McKay and Dr. Miral Mehta-Shounak.
Learning Objectives:
After this session, participants will be able to:
- Interpret and evaluate clinical trial data on biosimilars by analyzing key findings from pivotal ophthalmology studies and comparing their efficacy, safety, and real-world outcomes to reference biologics;
- Apply real-world evidence to clinical practice by examining case studies and identifying strategies to overcome challenges in biosimilar adoption across various ophthalmic settings;
- Navigate regulatory and practical considerations by understanding Health Canada’s biosimilar guidelines and examining reimbursement models and access barriers within Canada;
- Engage in expert-led discussions to gain insights on the evolving role of biosimilars and address common questions and concerns through interactive Q&A.
Submit Your OCT Case – Win a COS Prize!
Have a compelling AMD or DME case? Share it for a chance to be featured during our live case-based learning segment! Selected cases will be reviewed by our expert panel, and the top submission will receive a COS prize.
Submission Guidelines:
- Max 3 PowerPoint slides
- Include a brief patient history and OCT image(s)
- Pose a clinical question (e.g., “Should I switch this patient to a biosimilar?”)
Don’t miss this opportunity to showcase your case and gain expert insights! All cases should be submitted to [email protected] by May 23rd, 2025.
Whether you’re already considering biosimilars in your practice or simply want to stay ahead of the curve, this webinar offers a timely and comprehensive overview tailored specifically for Canadian ophthalmologists.
This activity is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Ophthalmological Society. You may claim a maximum of 1.5 hours.
This webinar would not be made possible without our sponsors. Please click here for our list of sponsors and our disclosure page.